Psychiatr. pro Praxi, 2001; 5: 227-229

Algoritmus léčby premenstruální dysforické poruchy

MUDr. Klára Látalová, doc. MUDr. Vladimír Pidrman Ph.D
Psychiatrická klinika FN a LF UP, Olomouc

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Látalová K, Pidrman V. Algoritmus léčby premenstruální dysforické poruchy. Psychiatr. praxi. 2001;2(5):227-229.

Premenstruální dysforická porucha (PMDD) je diagnostikována především v zemích, kde je používána klasifikace DSM-IV, neboť MSK-10 tuto diagnózu prakticky neuvádí (kategorii F 38.8 nelze považovat za jednotku vystihující náplň PMDD). Vyskytuje se několik dní před menstruací, nejdéle po celou dobu luteální fáze.

Premenstruálním syndromem, což je kvalitativně i kvantitativně méně závažná forma poruchy, trpí podle různých studií 50-75 % žen ve fertilním věku. PMDD postihuje 2-8 % žen. Jde o číslo vysoké, uvědomíme-li si, že po stránce pracovní a sociální ženu omezuje v dané dny obdobně jako depresivní fáze. Závažnost chorobného prožitku je rovněž srovnatelná s depresí, i když je časově samozřejmě kratší.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Psychiatric Association: DSM-IV. Washington, DC, APA, 1998, pp. 358.
    2. Angst, J. (1999): Premenstrual dysphoria. Eur. Neuropsychopharmacology, 9, 144 pp. Go to original source...
    3. Bach-y-Rita, P. (1994): Psychopharmacologic drugs: Mechanism of action. Science, 264, 642-644. Go to original source...
    4. Eriksson, E. (1999): Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int. Clin. Psychopharmacol., 14, suppl. 2, 27-33.
    5. Freeman, E. W., Rickels, K., Sondheimer, S. J. et al. (1999): Differential response to antidepressants in women with premenstrual syndrome / premenstrual dysphoric disorder. Arch. Gen. Psychiatry, 56, 932-939. Go to original source... Go to PubMed...
    6. Jermain, M. D., Preece, C. K., Sykes, R. et al. (1999): Lutheal phase sertraline treatment for premenstrual dysphoric disorder. Arch. Family Med., 8, 328-332. Go to original source... Go to PubMed...
    7. Mezinárodní klasifikace nemocí, 10. revize: Duševní poruchy a poruchy chování. PCP, Praha, 2000, 306 pp.
    8. Mortols, J. F. (1996): Premenstrual syndrome. Trends Endocrinol. Metab., 7, 184-189. Go to original source... Go to PubMed...
    9. Pidrman, V. (2000): Antidepresiva v léčbě chronické bolesti. Psychiatrie pro praxi, 1, 2, pp. 53-55.
    10. Pidrman, V., Látalová, K. (2001): Premenstruální dysforická porucha. Psychiatrie pro praxi, 2, 2, pp. 58-61.
    11. Rapkin, A., Laughlin, D. (1999): Guidelines for the treatment of premenstrual syndrome. Fam. Prac. Recent., 21, 51 pp..
    12. Robertson, M. M., Katona, C. L. E. (1997): Depression and physical illness. Chichester, John Wiley and Sons Ltd, 564 pp.
    13. Roca, C. A. (1999): Estrogen and mood in premenstrual women. Mood and psychotic disorders in women: an update on treatment. APA educational program, Washington, DC, APA, 28-41.
    14. Roca, C. A., Rosenstein, D. L., Schmidt, P. J. et al. (1996): Mechanism of efficacy of fluoxetine in premenstrual syndrom. Biol. Psychiatry, 39, 646 pp. Go to original source...
    15. Rubinow, D. R., Schmidt, P. J., Roca, C. A. (1998): Estrogen-serotonin interactions: implications for affective regulation. Biol. Psychiatry, 44, 839-850. Go to original source... Go to PubMed...
    16. Stahl, S. M. (2000): Essential psychopharmacology of depression and bipolar disorder. Cambridge university press, New York, 176 pp.
    17. Stahl, S. M. (1997): Sex therapy in psychiatric treatment has a new partner: reproductive hormones. J. Clin. Psychiatry, 58, 468-469. Go to original source... Go to PubMed...
    18. Steinberg, S. (1991): The treatment of late lutheal dysphoric disorder. Life Sci., 19, 767-802. Go to original source... Go to PubMed...
    19. Steiner, M. (1997): Premenstrual syndromes. Ann. Rev. Med., 48, 447-455. Go to original source... Go to PubMed...
    20. Steiner, M. (2000): Premenstrual dysphoric disorder: new research. Reproductive psychiatry: an update on womens health. Scientific Therapeutics Information, Chicago, 13-24.
    21. Steiner, M., Yonkers, K. (1999): Depression in women. London, Martin Dunitz, Ltd, 102 pp.
    22. Tasman, A., Kay, J., Lieberman, J. A. (1998): Pocket companion to accompany psychiatry. Philadelphia, W.B. Sounders Comp., 631 pp.
    23. Viguera, A. C. (2000): SSRIs in the treatment of PMDD: a critical review. Advances in womens mental health: a decade of progress. Educational program APA, Chicago, APA, 21-35.
    24. Wikander, I., Sundblad, C., Andersch, B. et al. (1998): Citalopram in premenstrual dysphoria. J. Clin. Psychopharmacol., 18, 360-390. Go to original source... Go to PubMed...
    25. Yonkers, K. (1997): Anxiety symptoms and anxiety disorders: How are they related to premenstrual disorders? J. Clin. Psychiatry, suppl. 3, 62-67.
    26. Yonkers, K. (1997): The association between premenstrual dysphoric disorder and other mood disorder. J. Clin. Psychiary, 58, suppl. 15: 19-25.
    27. Zweifel, J. E., O Brien, W. H. (1997): A meta-analysis of the effect of hormone replacement therapy upon depresses mood. Psychoneuroendocrinology, 22: 189-212. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.